These findings are similar to a study in the ZSF1 (obese, diabetic and hypertensive) rat DKD model where UD-014, an orally active SSAO inhibitor, demonstrated a significant and dose dependent reduction in albuminuria with a similar potency to losartan. Here, AOC3 is linked to diabetic kidney disease.